Scott Kanner

Head of Platform Development and Co-Founder

Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need.

Stablix

biotechnology

scott.kanner@stablix.com


Kevin Sprott
SVP of Drug Discovery and Co-Founder
Stablix
Biotechnology
United States
Carlo Rizzuto
Interim CEO
Stablix
Biotechnology